The ingredient – described by Indena as a ‘proprietary complex of curcumin (Curcuma longa L.) that is capitalizing the basic tenets of the Phytosome strategy to improve the bioavailability’ – can reportedly increase bioavailability over 20-fold.
“Using humble turmeric in a clinical trial to develop a new product is incredibly innovative, leading to the development of a safe and effective product that can be delivered at clinically realistic dosages - at a weight-to-weight price that's comparable with standard 95 per cent extracts,” said the award’s judges.
“We’re very pleased to receive this award” said Christian Artaria, Indena marketing director and head of functional food development at the prize gala ceremony “Indena’s model of identifying research and industrial collaborations ranging from R&D Institutions to hospitals and private clinics early in the product development cycle has again proven effective in shortening the time to market with this exciting product”.